Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shenzhen - Delayed Quote CNY

Shandong Sito Bio-technology Co., Ltd. (300583.SZ)

20.10
+0.84
+(4.36%)
At close: 3:04:40 PM GMT+8
Loading Chart for 300583.SZ
  • Previous Close 19.26
  • Open 19.14
  • Bid 20.07 x --
  • Ask 20.09 x --
  • Day's Range 19.30 - 20.30
  • 52 Week Range 10.66 - 31.63
  • Volume 4,034,118
  • Avg. Volume 4,412,172
  • Market Cap (intraday) 3.813B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.64
  • Earnings Date --
  • Forward Dividend & Yield 0.45 (2.34%)
  • Ex-Dividend Date Jul 30, 2024
  • 1y Target Est --

Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a methyl epoxide, and hexahydro-3a-methyl, as well as androsta-1,4-diene-3,17-dione and estra-4,9-diene-3,17-dione. The company was founded in 2002 and is based in Heze City, China.

www.sitobiotech.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 300583.SZ

View More

Performance Overview: 300583.SZ

Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

300583.SZ
2.81%
SSE Composite Index (000001.SS)
1.06%

1-Year Return

300583.SZ
34.51%
SSE Composite Index (000001.SS)
5.58%

3-Year Return

300583.SZ
64.13%
SSE Composite Index (000001.SS)
10.48%

5-Year Return

300583.SZ
28.65%
SSE Composite Index (000001.SS)
15.22%

Compare To: 300583.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300583.SZ

View More

Valuation Measures

Annual
As of 4/30/2025
  • Market Cap

    3.65B

  • Enterprise Value

    4.20B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.83

  • Price/Book (mrq)

    2.02

  • Enterprise Value/Revenue

    4.26

  • Enterprise Value/EBITDA

    115.33

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -9.15%

  • Return on Assets (ttm)

    -0.15%

  • Return on Equity (ttm)

    -5.13%

  • Revenue (ttm)

    970.6M

  • Net Income Avi to Common (ttm)

    -88.77M

  • Diluted EPS (ttm)

    -0.64

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    255.96M

  • Total Debt/Equity (mrq)

    40.41%

  • Levered Free Cash Flow (ttm)

    273.51M

Research Analysis: 300583.SZ

View More

Company Insights: 300583.SZ

Research Reports: 300583.SZ

View More

People Also Watch